Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
Open Access
- 2 August 2019
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-14
Abstract
Hypomethylating agents decitabine and azacytidine are regarded as interchangeable in the treatment of acute myeloid leukemia (AML). However, their mechanisms of action remain incompletely understood, and predictive biomarkers for HMA efficacy are lacking. Here, we show that the bioactive metabolite decitabine triphosphate, but not azacytidine triphosphate, functions as activator and substrate of the triphosphohydrolase SAMHD1 and is subject to SAMHD1-mediated inactivation. Retrospective immunohistochemical analysis of bone marrow specimens from AML patients at diagnosis revealed that SAMHD1 expression in leukemic cells inversely correlates with clinical response to decitabine, but not to azacytidine. SAMHD1 ablation increases the antileukemic activity of decitabine in AML cell lines, primary leukemic blasts, and xenograft models. AML cells acquire resistance to decitabine partly by SAMHD1 up-regulation. Together, our data suggest that SAMHD1 is a biomarker for the stratified use of hypomethylating agents in AML patients and a potential target for the treatment of decitabine-resistant leukemia.Keywords
This publication has 64 references indexed in Scilit:
- Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromesAnnals of Hematology, 2018
- Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemiaExpert Review of Hematology, 2018
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyThe Lancet Oncology, 2018
- Azacitidine in adult patients with acute myeloid leukemiaCritical Reviews in Oncology/Hematology, 2017
- A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersClinical Epigenetics, 2016
- A High-Throughput Enzyme-Coupled Assay for SAMHD1 dNTPaseSLAS Discovery, 2015
- Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemiaBlood, 2015
- Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screenScientific Reports, 2015
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometryJournal of Immunological Methods, 1991